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OVERVIEW
The plasma supply for pharmaceutical manufacturing con-
sists of surplus plasma recovered from whole blood collection 
and source plasma from plasmapheresis in Korea. Shortages 
are typically covered by importation. The total plasma sup-
ply for fractionation was 608,352 liters in 2009, of which 
430,267 liters were supplied domestically. The self-suffi-
ciency rate was, therefore, about 71% in terms of domestic 
demand.
  The fundamental policy for supplying plasma derivatives 
was established by the government in 1978 following the 
recommendations of WHO and IFRC (International Federa-
tion of Red Cross), based on ‘blood self-sufficiency’ and 
‘exclusion of commercialism’. Since then, the government 
has been maintaining a public arrangement for plasma frac-
tionation and authorized the delegation of supplying plasma 
and plasma products to the Korean Red Cross (KRC) through 
the revision of Pharmaceutical Affairs Law in 1986.
  According to this policy, permission for fractionation and 
importation, inspection of potentially importing blood col-
lection centers, and regular audits of plasma importers, have 
been all granted and executed by KRC. Moreover, KRC 
pushed ahead with its plan to produce end-products, and 
built a plasma fractionation center in 1991. However, the 
original plan was abandoned due to over-investment dis-
putes, and currently, KRC processes plasma to manufacture 
only a few intermediate produ c t s  s u c h  a s  2 0 %  a l b u m i n  
solution, immunoglobulin fraction, and cryoprecipitate. 
These intermediaries are purchased and further manufac-
tured to end-products by the pharmaceutical companies - 
Green Cross and SK Chemical.
  Thanks to the public management policy, the price of 
domestic plasma products has been maintained at a moderate 
level compared to other countries, and the domestic fractio-
nators have been able to improve their competitiveness.  
On the other hand, the current manufacturing chain has 
somewhat unreasonable aspects. This systematic absurdness 
has been a real obstacle to achieve plasma self-sufficiency 
until today.
FRACTIONATION PROCESS OF PLASMA DERIVATIVES
To make final products from recovered or apheresis plasma, 
frozen plasma must be thawed and processed through several 
steps. Through centrifugation and ethanol precipitation, co-
agulation factor IX, coagulation factor VIII (FVIII), fraction 
II (used as fibrin sealant), immunoglobulin (IG), fraction 
IV (anti-thrombin), and fraction V (processed to albumin) 
are fractionated respectively. One liter of plasma produces 
0.63 bottles (250 units/bottle) of FVIII, 1.5 bottles (50 
mL/bottle) of IG, and 1.4 bottles (100 mL/ bottle) of 20% 
albumin.
  Green Cross produces 12 kinds of end-products, while 
SK Chemical makes only two. The market share of Green 
Cross is about 87% of total sales in 2009. Among pharmaceut-
ical products, tetanus IG, hepatitis-B IG, and Varicella zoster 
IG require special plasma, which should be imported as 
the Blood Control Act in Korea prohibits paid donations 
of such blood. Total sales were about 178 billion KRW 
in 2009 (Table 1).Korean J Hematol 2010;45:3-5.
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Fig. 1. (A) Global and (B) domestic market share of plasma products.
Table 1. Domestic market share of plasma products sales in recent 3 years (billion KRW).
Products
2007 2008 2009
SK GC Subtotal SK GC Subtotal SK GC Subtotal
Albumin 19.6 49.7 69.3 21.4 43.9 65.3 24.8 52.1 76.9
IV immunoglobulin 2.9 11.2 14.1 3.7 12.4 16.1 4.1 15.5 19.6
Tetanus IG 0.8 9.8 10.6 0 10.8 10.8 0 13.1 13.1
HBV IG 0.7 30.4 31.1 0 36.7 36.7 0 42.3 42.3
Antithrombin − 11.0 11.0 − 12.6 12.6 − 15.6 15.6
Factor VIII − 33.1 33.1 − 30.2 30.2 − 36.7 36.7
Factor IX − 0.2 0.2 − 0.3 0.3 − 0.5 0.5
Varicella zoster IG − 0.04 0.04 − 0.05 0.05 − 0.04 0.04
Gamma globulin − 0.03 0.03 − 0.03 0.03 − 0.04 0.04
Histobulin − 0.3 0.3 − 0.3 0.3 − 3.5 3.5
Fibrin sealant − 5.4 5.4 − 6.3 6.3 − 9.6 9.6
Fibrinogen − 0.03 0.03 − 0.01 0.01 − 0.01 0.01
Total 24.0 151.2 175.2 25.1 153.6 178.7 28.9 188.9 217.8
Abbreviations: SK, SK Chemicals; GC, Green Cross
RECENT CHANGES IN THE GLOBAL AND DOMESTIC 
MARKET
Demand for plasma for fractionation is about 25 million 
liters annually worldwide, of which the United States sup-
plies about 64%, primarily due to the commercialized blood 
system. Most other countries have a voluntary, non-remun-
erated plasma donation policy.
  Among all the plasma products, global market share for 
IG is approximately 43%, while that of albumin is a mere 
13%.  As medical indications for IG steadily expand, the 
demand for IG is expected to increase 5-8% annually until 
2012. Conversely, controversies about the efficacy of albu-
min are likely to cause gradual decrease in demand. There 
is a striking contrast in Korea. The market share for albumin 
is 35-40% and that of IG less than 9% (Fig. 1). The remarkable 
consumption of albumin is due to a traditional tendency 
toward prescription, and without groundbreaking regu-
lations, such over-consumption practice seems to continue 
for some time. The demand for IG, on the other hand, 
is likely to increase steadily. The demand for coagulation 
factors is expected to diminish, as the recombinant products 
are gradually replacing the plasma derived products.
  The global plasma products’ price has greatly fluctuated 
due to demand-supply imbalance during recent decades. 
Although the current situation is much stabilized than be-
fore, the price of imported plasma can fluctuate at any 
time depending upon the global market situation and this 
is another reason why self-sufficiency is to be achieved.
SUPPLY PROSPECTS IN KOREA
Our definition for plasma self-sufficiency should be set pri-Korean J Hematol 2010;45:3-5.
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Table 2. Changes of domestic and imported plasma supply in
recent 5 years.
Year
Domestic 
plasma (L)
Imported 
plasma (L)
Total (L)
Self-sufficiency 
rate (%)
2005 317,329 309,296 626,625 50.6
2006 419,874 210,178 630,052 66.6
2007 300,795 350,526 651,321 46.2
2008 334,259 266,535 600,794 55.6
2009 430,267 178,085 608,352 70.7
marily based on albumin demand - the largest portion of 
all plasma products. Therefore, with considering the fact 
of an increasing trend of IG demand, the total domestic 
plasma demand for fractionation hovers at about 650,000 
liters. Subtracting 50,000 to 100,000 liters for special plasma, 
which should be imported, a real target for plasma self-suffi-
ciency will be 550,000 to 600,000 liters.
  After introducing plasmapheresis in 1991, KRC’s plasma 
collection number reached 465,350 in 2009. The widespread 
awareness of donors on the importance of plasma donation 
as well as the construction of blood donation centers has 
played a significant role in this remarkable growth.   
However, the blood shortages for transfusion have always 
affected the plasma supply as KRC should prioritize the 
needs of fresh blood products. Reviewing the plasma supply 
over the past 5 years, the plasma self-sufficiency rate dropped 
to a low of 46% in 2007, correlating with a serious domestic 
shortage of whole blood (Table 2). The reconstruction-asso-
ciated prolonged shutdown period of KRC’s new plant in 
that year was another contributing factor. As the donation 
number increased, the plasma self-sufficiency rate restored 
up to 71% in 2009. Considering about 2.57 million donations 
in 2009 and given our target as 600,000 liters a year, the 
additional collection of 340,000 liters of plasma will meet 
the achievement of plasma self-sufficiency. With the con-
tinuous improvement in the donor recruitment and re-
tention, this seems to be a reasonably achievable goal.
PROBLEMS AND SUGGESTIONS
There are several unreasonable contradictions as potential 
threats in current plasma supply chain. Most important fac-
tor is that the plasma and intermediaries’ price is determined 
by the negotiation between KRC and pharmaceutical 
companies. So the increase of collection and processing cost 
can hardly be compensated appropriately. This can lead 
to financial problems of KRC in terms of operating blood 
centers and plasma fractionation center. The cost for aphe-
resis plasma has been continuously increased due to several 
factors such as implementation of nucleic acid amplification 
test or inventory hold to improve the blood safety. The 
periodic review of the plasma pricing and setting by the 
government in accordance with the end-product price-set-
ting seems to be imperative to solve this situation.
  Current dual pricing system for recovered and apheresis 
plasma due to the difference of collection cost forces KRC 
plasma fractionation center’s operation rate below optimal 
level. So the adoption of dual pricing system for inter-
mediaries according to the raw material cost difference to 
enhance the KRC fractionation center’s efficiency should 
be considered.
  Lastly, we should think about the original idea of KRC’s 
role in the public management policy of plasma products. 
In Japan, the donors easily accept the concept of plasma 
self-sufficiency and donate plasma because Japanese Red 
Cross, a well-known non-profit organization, manufactures 
several kinds of end-products. Meanwhile in Korea, some 
people have a doubt that the donated plasma is just used 
to make pharmaceutical manufacturers’ profits. So, the ideal 
role and responsibility of KRC and pharmaceutical industry 
should be discussed and settled to maximize the public inter-
est and to achieve the goal of plasma self-sufficiency.